-
Recombinant Human Growth Hormone in Chondrocyte Assays
2026-08-18
Use Recombinant Human Growth Hormone as a defined stimulus for chondrocyte proliferation, hypertrophic differentiation, and IGF-1 pathway studies. This workflow connects growth hormone receptor activation with the IGFBP2-THBS1 mechanism described in recent idiopathic short stature research while providing practical controls for reproducible cell assays.
-
Amyloid β-Peptide (1-42) (human) Assay Guide
2026-08-18
A scenario-based guide to designing more interpretable Aβ42 peptide viability, cytotoxicity, and microglial assays. It explains how SKU B6057 can support controlled preparation, concentration selection, storage, and vendor evaluation in Alzheimer’s disease research.
-
Lanabecestat (AZD3293) for BACE1 Assays
2026-08-17
Lanabecestat (AZD3293) enables high-affinity BACE1 pathway studies that connect amyloid-beta secretion with neuronal function. This workflow-focused guide shows how to establish exposure-response windows, pair biochemical and optical electrophysiology readouts, and troubleshoot synaptic or assay variability.
-
NLRP10, Keratinocyte Survival, and AD Barrier Function
2026-08-17
The reference study identifies NLRP10 as a regulator of epidermal homeostasis, linking reduced NLRP10 expression in atopic dermatitis with caspase-8-dependent keratinocyte death, impaired P63 activity, and defective barrier formation. Its human skin equivalent model provides a useful framework for separating disease association from functional mechanisms and for evaluating barrier-restoring strategies.
-
Anti-RPS6 Antibody: PDAC Workflow Guide
2026-08-16
Translate LRRC8A–Caveolin-1 biology into practical RPS6 readouts with one unconjugated monoclonal antibody for Western blot, ICC/IF, and immunoprecipitation. This guide shows how to connect total RPS6 abundance with signaling, ribosome-associated biology, and growth phenotypes while avoiding overinterpretation of total-protein data.
-
Sumatriptan Metabolism: CYP and MAO Revisited
2026-08-15
The reference study revises the established view that sumatriptan is degraded mainly through monoamine oxidase A, showing that selected CYP enzymes also drive sequential N-demethylation. Its recombinant-enzyme and HPLC–MS workflow provides a practical framework for distinguishing parallel and sequential oxidative pathways in neuroactive drug metabolism.
-
(R,S)-Anatabine Workflows for Aβ Research
2026-08-14
(R,S)-Anatabine supports mechanism-focused Alzheimer’s studies that connect APP β-cleavage, BACE-1 expression, soluble Aβ peptide reduction, and NF-κB signaling in one workflow. This guide translates those properties into reproducible cell-based and animal-model assays, with practical controls for solvent handling, matrix effects, and interpretation.
-
Amyloid β-Peptide (1-42): Applied AD Workflows
2026-08-14
Build reproducible Aβ42 peptide workflows for neuronal toxicity, microglial phagocytosis, and ion-channel studies. This guide connects peptide-state control with practical assay design, quantified starting conditions, and troubleshooting strategies for Alzheimer’s disease research.
-
GANT61 in ALK-Positive ALCL: Cell-Cycle Mechanisms
2026-08-13
The 2026 Annals of Hematology study identifies GANT61 as an inhibitor of proliferation and an inducer of cell-cycle arrest and apoptosis in ALK-positive anaplastic large cell lymphoma. Its central mechanistic contribution is connecting Gli1 inhibition with PIK3IP1 upregulation and reduced Akt phosphorylation, suggesting an Hh–PIK3IP1–Akt signaling axis in ALK-positive ALCL biology.
-
EZ Cap Cy5 Firefly Luciferase mRNA Workflows
2026-08-13
Track both where an mRNA goes and whether it produces protein with a single dual-reporter reagent. This guide turns Cy5 fluorescence and Firefly luciferase into a practical framework for mRNA delivery and transfection, carrier comparison, intracellular trafficking, and in vivo bioluminescence imaging.
-
Partial BACE1 Inhibition and Synaptic Transmission
2026-08-12
Satir et al. tested whether moderate β-secretase inhibition could reduce amyloid-beta secretion without compromising neuronal communication. Their optical electrophysiology study found that reductions below 50% preserved synaptic transmission in cultured cortical neurons, whereas stronger inhibition was associated with synaptic suppression.
-
ML365: An Assay-to-Mechanism Research Guide
2026-08-12
ML365 is a selective TASK1 channel probe that connects membrane-potential biology with hippocampal inflammation. This guide explains how to interpret its orthogonal potency data, design mechanism-aware experiments, and evaluate the limits of pharmacological evidence.
-
PD 173074: FGFR1 Signaling and Assay Strategy
2026-08-11
PD 173074 is a selective FGFR1 and VEGFR2 pathway inhibitor for mechanistic cancer research and translational assay development. This guide connects its ATP-competitive pharmacology with a 2025 genetic and docking study that positions FGFR1 as a testable schizophrenia target.
-
ML365: From TASK1 Blockade to Neuroinflammation
2026-08-11
ML365 is a selective TASK1 potassium-channel probe that connects membrane-potential biology with hippocampal inflammation. This article explains how to interpret its orthogonal potency data, design mechanism-aware experiments, and evaluate its role in target validation for potassium channels.
-
Erastin Workflow for Ferroptosis Research
2026-08-10
Use Erastin to expose redox vulnerabilities in RAS- or BRAF-altered tumor models while separating ferroptosis initiation from late plasma-membrane failure. This practical workflow combines dose planning, lipid-ROS measurements, genotype-aware comparisons, and membrane-integrity assays inspired by recent ferroptosis research.